Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Director | January 02, 2023 | January 04, 2023 |
| EyePoint, Inc.EYPT · Entity 5702 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 02, 2023 · Filed January 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2033-01-01 | Direct | 75,000 |
Reported balance
After 2023-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-02 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares of Common Stock underlying this award will vest in full on January 2, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock underlying this award will vest in full on January 2, 2024.
EyePoint, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2036-01-02 | Direct | 41,500 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 41,500 · Balance 41,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 16:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 41,500 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001110748-26-000002 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires 2036-01-02 Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 16:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 41,500 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000233 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires 2035-01-03 Read SEC document |
| August 21, 2024 Filed Aug 21, 2024 16:01 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 5,000 | $7.95 | $39,750.00 |
DisclosureSEC source: 0001562180-24-006432 · primarydocument.xml · nonDerivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,150 Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 20:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 23,598 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000392 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,598 Underlying: Common Stock · 23,598 shares Expires 2034-01-04 Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 09:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001562180-23-005448 · primarydocument.xml · derivative · entry 2 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2033-06-19 Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 09:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 27,100 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-23-005448 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,100 Underlying: Common Stock · 27,100 shares Expires 2033-06-19 Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 17:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 3,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-001334 · primarydocument.xml · derivative · entry 2 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date. F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 17:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-001334 · primarydocument.xml · nonDerivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:04 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000024 · wf-form4_167286986208199.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:48 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-22-001417 · primarydocument.xml · derivative · entry 4 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-02-09 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:48 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 2,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001417 · primarydocument.xml · derivative · entry 3 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date. F2 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:48 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 3,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001417 · primarydocument.xml · derivative · entry 2 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 3,250 shares Expires not disclosed F1 · derivative.exercise_date: Will fully vest on the one-year anniversary of the grant date. F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:48 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001417 · primarydocument.xml · nonDerivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:31 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001453687-22-000014 · wf-form4_164141824527967.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 3, 2023. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 17:29 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-21-004455 · primarydocument.xml · derivative · entry 2 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-02-09 Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 17:29 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 2,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004455 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 18:49 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001453687-21-000051 · wf-form4_161731730589915.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F1 · derivative.exercise_date: This option vests in full on March 30, 2022. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 19:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 2,150 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001818 · primarydocument.xml · derivative · entry 2 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 19:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001818 · primarydocument.xml · nonDerivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 16:42 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001453687-20-000044 · wf-form4_158810653092053.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: The option vests in thirty-six (36) substantially equal monthly installments over three years following the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:02 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 38,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002044 · primarydocument.xml · derivative · entry 2 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 38,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:02 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 21,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002044 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 16:50 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001562180-19-003663 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-21 Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 16:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0000899243-18-026697 · doc4.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-10-11 F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on October 11, 2019. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0000899243-18-018295 · doc4.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-06-25 F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on June 25, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.